Abstract
It is well-established that adults with polycystic ovary syndrome (PCOS) have an increased prevalence of several cardiometabolic risk factors, including obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidemia. Accumulating data suggest that these risk factors are already present in adolescence in patients with PCOS. This has major implications for the management of this population since the timely identification of these risk factors is essential for preventing cardiovascular disease in adulthood. The present review summarizes the existing evidence regarding the prevalence of traditional and non-traditional cardiometabolic risk factors in adolescents with PCOS.
Keywords: Polycystic ovary syndrome, adolescence, obesity, type 2 diabetes mellitus, hyperandrogenemia, anovulation.
Current Pharmaceutical Design
Title:Cardiometabolic Risk Factors in Adolescents with Polycystic Ovary Syndrome
Volume: 27 Issue: 36
Author(s): Anastasia Vatopoulou*, Maria-Eleni Dionelli, Alexis Papanikolaou and Sonia Grover
Affiliation:
- Second Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, 55133,Greece
Keywords: Polycystic ovary syndrome, adolescence, obesity, type 2 diabetes mellitus, hyperandrogenemia, anovulation.
Abstract: It is well-established that adults with polycystic ovary syndrome (PCOS) have an increased prevalence of several cardiometabolic risk factors, including obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidemia. Accumulating data suggest that these risk factors are already present in adolescence in patients with PCOS. This has major implications for the management of this population since the timely identification of these risk factors is essential for preventing cardiovascular disease in adulthood. The present review summarizes the existing evidence regarding the prevalence of traditional and non-traditional cardiometabolic risk factors in adolescents with PCOS.
Export Options
About this article
Cite this article as:
Vatopoulou Anastasia *, Dionelli Maria-Eleni , Papanikolaou Alexis and Grover Sonia , Cardiometabolic Risk Factors in Adolescents with Polycystic Ovary Syndrome, Current Pharmaceutical Design 2021; 27 (36) . https://dx.doi.org/10.2174/1381612826666201127123357
DOI https://dx.doi.org/10.2174/1381612826666201127123357 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Editorial (Thematic Issue: Natural Polyphenols and Diabetes: Understanding their Mechanism of Action)
Current Medicinal Chemistry Inhibition of Protein Tyrosine Phosphatase 1B as a Potential Treatment of Diabetes and Obesity
Current Pharmaceutical Design Endothelial Dysfunction in Morbid Obesity
Current Pharmaceutical Design Preface [Hot topic: Anti-Hypertensive Agents in Relation to Modifying Coronary Risk Factors (Executive Editor : Aurelio Leone)]
Current Pharmaceutical Design Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function
Current Pharmaceutical Design Withdrawn: Diabetes Mellitus Prognosis Using Fuzzy Logic and Neural Networks Case Study: Alexandria Vascular Center (AVC)
Recent Advances in Computer Science and Communications Gastroenterological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Anti-Diabetic Agents from Natural Products — An Update from 2004 to 2009
Current Topics in Medicinal Chemistry Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Current Vascular Pharmacology The Role of Intracellular 35-Cyclic Adenosine Monophosphate (cAMP) in Atherosclerosis
Current Vascular Pharmacology Inhibitors of the TGF-β Superfamily and their Clinical Applications
Mini-Reviews in Medicinal Chemistry Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry Vaccination Against High Blood Pressure
Current Pharmaceutical Design Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters
Current Topics in Medicinal Chemistry Synthesis, Characterization and Biological Activities of New Symmetric Bis-1,2,3-Triazoles with Click Chemistry
Medicinal Chemistry Role of Adipocytokines in Hepatic Fibrosis
Current Pharmaceutical Design Nitric Oxide Synthase and Cyclooxygenase Pathways: A Complex Interplay in Cellular Signaling
Current Medicinal Chemistry Effects of Dietary Iron Modulation on Gut Microbial Composition and Function in Monogastrics: A Review
Protein & Peptide Letters